

# Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.

**Title:** Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.

**Publication year:** 2021

**Journal:** Annals of internal medicine

**Authors:** National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.).

**Society:** European Society of Cardiology

**Origin country:** International (Europe)

**Target countries:** Europe

**DOI:** 10.7326/M20-6448

**PMID:** 32976026

**Source:** <https://pubmed.ncbi.nlm.nih.gov/32976026/>

Ann Intern Med Ann Intern Med 3925 pheamercphys 0372351 aim Annals of Internal Medicine 0003-4819 1539-3704 pmc-is-collection-domain yes pmc-collection-title American College of Physicians - PMC COVID-19 Collection PMC7556653 PMC7556653.1 7556653 7556653 32976026 10.7326/M20-6448 aim-olf-M206448 1 Special Articles coronavirus Coronavirus Disease 2019 (COVID-19) 3122457 COVID-19 2357 Health care providers 11279 SARS coronavirus 9715 Patients 6354 Upper respiratory tract infections 1541398 Pulmonary diseases 3282 Infectious diseases 8910 Epidemiology 7245 Lungs Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel Perspectives on Convalescent Plasma for COVID-19 Pau Alice K. PharmD Aberg Judith MD Baker Jason MD, MS Belperio Pamela S. PharmD Coopersmith Craig MD Crew Page PharmD, MPH Glidden David V. PhD Grund Birgit PhD Gulick Roy M. MD, MPH Harrison Carly MS Kim Arthur MD Lane H. Clifford MD Masur Henry MD Sheikh Virginia MD, MHS Singh Kanal MD, MPH Yazdany Jinoos MD, MPH Tebas Pablo MD \* for the National Institutes of Health COVID-19 Treatment Guidelines Panel\* 1 National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.) 2 Icahn School of Medicine at Mount Sinai, New York, New York (J.A.) 3 Hennepin Healthcare/University of Minnesota, Minneapolis, Minnesota (J.B.) 4 Department of Veterans Affairs, Los Angeles, California (P.S.B.) 5 Emory University School of Medicine, Atlanta, GA (C.C.) 6 University of California, San Francisco, San Francisco, California (D.V.G., J.Y.) 7 University of Minnesota, Minneapolis, Minnesota (B.G.) 8 Weill Cornell Medicine, New York, New York (R.M.G.) 9 LupusChat, New York, New York (C.H.) 10 Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts (A.K.) 11 Food and Drug Administration, Silver Spring, Maryland (V.S.) 12 University of Pennsylvania, Philadelphia, Pennsylvania (P.T.) Disclosures: Disclosures can be viewed at [www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-6448](http://www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-6448)

Corresponding Author: Alice K. Pau, PharmD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Room 11C103, Bethesda, MD 20892; e-mail, [apau@niaid.nih.gov](mailto:apau@niaid.nih.gov) .

Author Contributions: Conception and design: J. Aberg, J. Baker, P.S. Belperio, C.M. Coopersmith, P. Crew, B. Grund, C. Harrison, A.Y. Kim, H.C. Lane, A.K. Pau, V. Sheikh, K. Singh, P. Tebas, J. Yazdany.

Analysis and interpretation of the data: J. Aberg, A. Adimora, J. Baker, L.M. Baumann Kreuziger, R. Bedimo, P.S. Belperio, T. Burgess, D. Campbell, S.V. Cantrill, C.M. Coopersmith, P. Crew, E.S. Daar, S. Davis, A. Dzierba, L. Evans, J. Francis, J.J. Gallagher, R. Gandhi, D.V. Glidden, B. Grund, R.M. Gulick, E.J. Hardy, C. Harrison, C. Hinkson, B.L. Hughes, S.C. Johnson, M. Keller, A.Y. Kim,

S.S. Kuriakose, H.C. Lane, J.L. Lennox, A.M. Lerner, M.M. Levy, G.S. Martin, H. Masur, S. Naggie, M. Nason, A.K. Pau, A.T. Pavia, N. Seam, V. Sheikh, S.Q. Simpson, K. Singh, S. Swindells, P. Tebas, P. Tien, T.M. Uyeki, A. Waghmare, R. Walker, K.C. Wilson, J. Yazdany.

Drafting of the article: J. Aberg, J. Baker, P.S. Belperio, C.M. Coopersmith, P. Crew, B. Grund, C. Harrison, A.Y. Kim, H.C. Lane, A.K. Pau, V. Sheikh, K. Singh, P. Tebas, J. Yazdany.

Critical revision for important intellectual content: J. Aberg, A. Adimora, J. Baker, L.M. Baumann Kreuziger, R. Bedimo, P.S. Belperio, T. Burgess, D. Campbell, S.V. Cantrill, C.M. Coopersmith, P. Crew, E.S. Daar, S. Davis, A. Dzierba, L. Evans, J. Francis, J.J. Gallagher, R. Gandhi, D.V. Glidden, B. Grund, R.M. Gulick, E.J. Hardy, C. Harrison, C. Hinkson, B.L. Hughes, S.C. Johnson, M. Keller, A.Y. Kim, S.S. Kuriakose, H.C. Lane, J.L. Lennox, A.M. Lerner, M.M. Levy, G.S. Martin, H. Masur, S. Naggie, M. Nason, A.K. Pau, A.T. Pavia, N. Seam, V. Sheikh, S.Q. Simpson, K. Singh, S. Swindells, P. Tebas, P. Tien, T.M. Uyeki, A. Waghmare, R. Walker, K.C. Wilson, J. Yazdany.

Final approval of the article: J. Aberg, A. Adimora, J. Baker, L.M. Baumann Kreuziger, R. Bedimo, P.S. Belperio, T. Burgess, D. Campbell, S.V. Cantrill, C.M. Coopersmith, P. Crew, E.S. Daar, S. Davis, A. Dzierba, L. Evans, J. Francis, J.J. Gallagher, R. Gandhi, D.V. Glidden, B. Grund, R.M. Gulick, E.J. Hardy, C. Harrison, C. Hinkson, B.L. Hughes, S.C. Johnson, M. Keller, A.Y. Kim, S.S. Kuriakose, H.C. Lane, J.L. Lennox, A.M. Lerner, M.M. Levy, G.S. Martin, H. Masur, S. Naggie, M. Nason, A.K. Pau, A.T. Pavia, N. Seam, V. Sheikh, S.Q. Simpson, K. Singh, S. Swindells, P. Tebas, P. Tien, T.M. Uyeki, A. Waghmare, R. Walker, K.C. Wilson, J. Yazdany.

Statistical expertise: D. Glidden, B. Grund, M. Nason.

Administrative, technical, or logistic support: P. Crew, S.S. Kuriakose, A.M. Lerner, A.K. Pau, K. Singh.

25 9 2020 366899 M20-6448 14 10 2020 23 10 2020 30 03 2024 2020 American College of Physicians This article is made available via the PMC Open Access Subset for unrestricted re-use for research, analyses, and text and data mining through PubMed Central. Acknowledgement of the original source shall include a notice similar to the following: "© 2020 American College of Physicians. Some rights reserved. This work permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited." These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.